** Shares of biotechnology firm AnaptysBio fall ~29% to $21.99 premarket
** Pharma giant Eli Lilly , in an investor presentation, discloses it has dropped ANAB's PD-1 agonist peresolimab to treat rheumatoid arthritis from its pipeline
** "The clinical program's discontinuation is a negative for perception of ANAB's PD-1 agonist rosnilimab," analysts at Leerink Partners wrote in a note
** As of last close, ANAB up ~44% YTD
(Reporting by Manya Saini in Bengaluru)
((Manya.Saini@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。